Anti-TNFα therapy in ankylosing spondylitis: Symptom control and structural damage modification;Terapia anti-TNFα en espondilitis anquilosante: control sintomático y modificación del daño estructural

Reumatologia Clinica

Volumn 7, Issue 1, 2011, Pages 51-55

  Andreu, José Luis ^a   Otón, Teresa ^a   Sanz, Jesús ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Da o estructural; Espondilitis anquilosante; Structural damage; Terapia anti TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANKYLOSING SPONDYLITIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; SHORT SURVEY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651361751     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.03.007     Document Type: Short Survey

References (35)

1. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of inmunohistologic and in situ hibridization tecniques in the examination of the sacroiliac joints from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
2. Van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of Infliximab in patients with Ankylosing Spondylitis. Arthritis Rheum 2005, 52:582-591.
3. Calin A., Dijkmans B.A.C., Emery P., Hakala M., Kalden J., Leirisalo-Repo M., et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594-1600.
4. Van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A.C., Braun J., et al. Efficacy and safety of Adalimumab in patients with Ankylosing Spondylitis. Arthritis Rheum 2006, 54:2136-2146.
5. Inman R., Davis J.C., Van der Heijde D., Diezman L., Sieper J., Kim S., et al. Efficacy and safety of Golimumab in patients with Ankylosing Spondylitis. Arthritis Rheum 2008, 58:3402-3412.
6. Braun J., McHugh N., Singh A., Wajdula J.S., Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly. Rheumatology (Oxford) 2007, 46:999-1004.
7. Braun J., Baraliakos X., Listing J., Fritz C., Alten R., Burmester G., et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
8. Davis C., van der Heijde D., Braun J., Dougados M., Clegg D.O., Kivitz A.J., et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008, 67:346-352.
9. Van der Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis, publicado on-line 13 agosto 2008.
10. Baraliakos X., Listing J., Fritz C., Alten R., Burmester G., Krause A., et al. Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years. Evidence for different response to anti-TNFα therapy. Ann Rheum Dis 2008, 67(Suppl II):375.
11. Carmona L., Gomez-Reino J.J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8:R72. BIOBADASER Group.
12. Baraliakos X., Listing J., Brandt J., Rudwaleit M., Sieper J., Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Research & Therapy 2005, 7:439-444.
13. Baraliakos X., Listing J., Rudwaleit M., Brandt J., Alten R., Burmester G., et al. Safety and efficacy of readministration of Infliximab after longterm continuous therapy and withdrawal in patients with Ankylosing Spondylitis. J Rheumatology 2007, 34:510-515.
14. Brandt J., Listing J., Haibel H., Sörensen H., Schwebig A., Rudwaleit M., et al. Long-term efficacy and safety of etanercept after readministration in patients with active Ankylosing Spondylitis. Rheumatology 2005, 44:342-348.
15. Breban M., Ravaud P., Claudepierre P., Baron G., Henry Y.-D., Hudry C., et al. Maintenance of Infliximab treatment in Ankylosing Spondylitis. Arthritis Rheum 2008, 58:88-97.
16. Conti F., Ceccarelli F., Marocchi E., Magrini L., Spinelli F.R., Spadaro A., et al. Switching tumour necrosis factor a antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66:1393-1397.
17. Delaunay C., Farrenq V., Marini-Portugal A., Cohen J.D., Chevalier X., Claudepierre P., et al. Infliximab to Etanercept switch in patients with Spondyloarthropathies and Psoriatic Arthritis: Preliminary Data. J Rheumatology 2005, 32:2183-2185.
18. Coates L.C., Cawkwell L.S., Ng N.W.F., Bennett A.N., Bryer D.J., Fraser A.D., et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008, 47:897-900.
19. Barkham N., Keen H.I., Coates L.C., O'Connor P., Hensor E.M.A., Fraser A.D., et al. A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA B27 positive very early ankylosing spondylitis. Ann Rheum Dis 2008, 67(Suppl II):382.
20. Amtenbrink A.L., Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R., et al. Efficacy of adalimumab in the treatment of patients with axial spondyloarthritis (SPA) and no radiographic sacroilitis: continuous adalimumab therapy is necessary to prevent relapses after treatment withdrawal. Ann Rheum Dis 2008, 67(Suppl II):373.
21. Landewé R, Dougados M, Mielants H, Van der Tempel H, Van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis, publicado on-line el 15 de Julio de 2008.
22. Baraliakos X., Davis J., Tsuji W., Braun J. Magnetic resonance imaging examinations of the spine in patients with Ankylosing Spondylitis before and after therapy with the Tumor Necrosis Factor α Receptor Fusion Protein Etanercept. Arthritis Rheum 2005, 52:1216-1223.
23. Maksymowych W.P., Inman R.D., Salonen D., Dhillon S.S., Williams M., Stone M., et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005, 53:703-709.
24. Baraliakos X., Davis J., Tsuji W., Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005, 52:1216-1223.
25. Sieper J., Baraliakos X., Listing J., Brandt J., Haibel H., Rudwaleit M., et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 2005, 44:1525-1530.
26. Baraliakos X., Listing J., Rudwaleit M., Sieper J., Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008, 10:R104.
27. Baraliakos X., Listing J., Rudwaleit M., Haibel H., Brandt J., Sieper J., et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007, 66:910-915.
28. Van der Heijde D., Landewé R., Baraliakos X., Houben H., Van Tubergen A., Williamson P., et al. Radiographic findings following two years of Infliximab therapy in patients with Ankylosing Spondylitis. Arthritis Rheum 2008, 58:3063-3070.
29. Van der Heijde D., Landewé R., Einstein S., Ory P., Vosse D., Ni L., et al. Radiographic progression of Ankylosing Spondylitis after up to two years of treatment with Etanercept. Arthritis Rheum 2008, 58:1324-1331.
30. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
31. Lories R.J., Derese I., de Bari C., Luyten F.P. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007, 56:489-497.
32. Wanders A., van der Heijde D., Landewé R., Béhier J.M., Calin A., Olivieri I., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with Ankylosing Spondylitis. Arthritis Rheum 2005, 52:1756-1765.
33. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., O'keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002, 109:1405-1415.
34. Ijiri K., Matsunaga S., Fukuda T., Shimizu T. Indomethacin inhibition of ossification induced by direct current stimulation. J Orthop Res 1995, 13:123-131.
35. Neal B., Rodgers A., Dunn L., Fransen M. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2000, 3:CD001160.